ArticleMutagenesis2023
Current status and future challenges of genotoxicity OECD Test Guidelines for nanomaterials: a workshop report.
Article in Mutagenesis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Developing a New Approach Methodology Framework to Assess Biological Responses to Nanoplastics: Insights from Polystyrene and Biodegradable Particles.Nanomaterials (Basel, Switzerland) · 2026Article
- Phytotoxic and Eustress Effects of Metal Oxide Nanoparticles (CuO, MnPlants (Basel, Switzerland) · 2026Review
- From In Vitro Genotoxicity Assays to Human Biomarkers: Interpreting DNA Damage Signals in Long-Term SSRI Therapy through a Translational Neurotoxicology Lens.Neurotoxicity research · 2026Review
- Nanoparticle-Based Approaches for Enhancing In Vitro Fertilization in Animal Reproduction.International journal of molecular sciences · 2026Review
- Tungsten carbide-cobalt can function as a particle positive control for genotoxicity in vitro in specific cell lines.Mutagenesis · 2025Article
- Nanotoxicity of Porous Silica Nanoparticles: Physicochemical Properties and Mechanistic Cellular Endpoints.Nanomaterials (Basel, Switzerland) · 2025Review
- Understanding the cellular uptake and genotoxic potential of industrial relevant nanomaterials utilizing electron microscopy and the ToxTracker assay in vitro.Mutagenesis · 2025Article
- Green-Synthesized Nanomaterials for Water Disinfection: Mechanisms, Efficacy, and Environmental Safety.Nanomaterials (Basel, Switzerland) · 2025Review
- The nano-paradox: addressing nanotoxicity for sustainable agriculture, circular economy and SDGs.Journal of nanobiotechnology · 2025Review
- 25 years of research and regulation: Is nanotechnology safe to commercialize?Frontiers in toxicology · 2025Review
- Hazard assessment of nanomaterials: how to meet the requirements for (next generation) risk assessment.Particle and fibre toxicology · 2024Article
- Toward Standardization of a Lung New Approach Model for Toxicity Testing of Nanomaterials.Nanomaterials (Basel, Switzerland) · 2024Article
- Mechanisms and Assessment of Genotoxicity of Metallic Engineered Nanomaterials in the Human Environment.Biomedicines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genotoxicity testing for nanomaterials remains challenging as standard testing approaches require some adaptation, and further development of nano-specific OECD Test Guidelines (TGs) and Guidance Documents (GDs) are needed. However, the field of genotoxicology continues to progress and new approach methodologies (NAMs) are being developed that could provide relevant information on the range of mechanisms of genotoxic action that may be imparted by nanomaterials. There is a recognition of the need for implementation of new and/or adapted OECD TGs, new OECD GDs, and utilization of NAMs within a genotoxicity testing framework for nanomaterials. As such, the requirements to apply new experimental approaches and data for genotoxicity assessment of nanomaterials in a regulatory context is neither clear, nor used in practice. Thus, an international workshop with representatives from regulatory agencies, industry, government, and academic scientists was convened to discuss these issues. The expert discussion highlighted the current deficiencies that exist in standard testing approaches within exposure regimes, insufficient physicochemical characterization, lack of demonstration of cell or tissue uptake and internalization, and limitations in the coverage of genotoxic modes of action. Regarding the latter aspect, a consensus was reached on the importance of using NAMs to support the genotoxicity assessment of nanomaterials. Also highlighted was the need for close engagement between scientists and regulators to (i) provide clarity on the regulatory needs, (ii) improve the acceptance and use of NAM-generated data, and (iii) define how NAMs may be used as part of weight of evidence approaches for use in regulatory risk assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.